Irene M. Hramiak MD, FRCP(C), MACP
Professor, Department of Medicine, Division of Endocrinology and Metabolism, Western University; Department of Medicine Site Chief, St. Joseph’s Hospital; Endocrinologist, St. Joseph’s Health Care London, London, Ontario, CanadaIrene M. Hramiak, MD, FRCP(C), MACP, is a Professor of Medicine, Western University, London, ON. She is the current Department of Medicine Site Chief at St. Joseph’s Hospital.
Dr. Hramiak practices Endocrinology at St. Joseph’s Hospital in London, Ontario, with a strong clinical interest in Type 1 and Type 2 diabetes mellitus.
Dr. Hramiak has held peer reviewed funding from JDRF, CDA, and the NIH since 1983; she was a co-investigator in the DCCT (1983-2000), for which she was awarded the Charles H. Best Award for distinguished service by the American Diabetes Association in 1993. In 2016, she was awarded the Canadian Diabetes Association’s Gerald S Wong Service Award. She has been a Principle Investigator in many cardiovascular outcome trials in Type 2 diabetes mellitus, including: ACCORD, ORIGIN, TECOS, LEADER, SUSTAIN, REWIND, and DECLARE-TIMI 58. Dr. Hramiak was the Principle Investigator at Western University for the JDRF Ontario trial network. She has been a Principle Investigator for REMOVAL and other trials investigating benefits of new therapies in Type 1 Diabetes.
Dr. Hramiak has been recognized by ACP with a Mastership for Academic Excellence in 2020. Western University has awarded her the Alumni of Distinction Award in 2021.
Dr. Hramiak serves as an external advisor to many groups and pharmaceutical companies with regards to diabetes and obesity.
Disclosures
Dr. Hramiak reports the following:- Grants/Research Support: Novo Nordisk, Sanofi, Eli Lilly
- Speakers Bureau/Honoraria:Bayer Inc., Boehringer Ingelheim, Eli Lilly, Insulet, Merck, Novo Nordisk
- Consulting Fees: Boehringer Ingelheim, Eli Lilly, Medtronic, Merck, Novo Nordisk, Sanofi
- Other: Employee of Western University